Search Results | Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Abstract CT233: A phase I study evaluating continuous and intermittent AZD2014 in combination with fulvestrant in patients with ER+ advanced metastatic breast cancer

Manish Patel, Erika Hamilton, Patricia M. LoRusso, W. Larry Gluck, Suzanne F. Jones, Muaiad Kittaneh, Sabina Cosulich, Elizabeth A. Harrington, Stephen Green, Wendy Burke, Donald K. Strickland, Elisabeth Oelmann, Howard A. Burris

Cancer Res (2015) 75 (15_Supplement): CT233.

DOI: https://doi.org/10.1158/1538-7445.AM2015-CT233

Published: 01 August 2015

View article

Journal Articles

Abstract 4696: Combining AZD8186, an inhibitor of PI3Kbeta, with inhibitors of PI3Kalpha and mTORC1/2 gives comprehensive pathway suppression and enhanced antitumor activity in PTEN null tumors

Urs Hancox, Urszula Polanska, James T. Lynch, Carol Lenaghan, Cath Trigwell, Oona Depuelch, Phillippa Dudley, Juliana Maynard, Lara Ward, Kevin Hudson, Jon Curwen, Francisco Cruzalegui, Stephen Green, Klinowska Teresa, Simon T. Barry

Cancer Res (2015) 75 (15_Supplement): 4696.

DOI: https://doi.org/10.1158/1538-7445.AM2015-4696

Published: 01 August 2015

View article

Journal Articles

Abstract 4719: Targeting interdependent signaling pathways to increase the durability and magnitude of response: promising combination therapy with dual mTORC1/2 inhibitors and CDK4/6 inhibitors

Claire Crafter, Jon Curwen, Oona Delpuech, Lenka Oplustilova, Stephen Green, Henry Brown, Cath Trigwell, Sabina Cosulich

Cancer Res (2015) 75 (15_Supplement): 4719.

DOI: https://doi.org/10.1158/1538-7445.AM2015-4719

Published: 01 August 2015

View article

Journal Articles

Abstract 2830: Discovery of AZD8835, a potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of PIK3CA-dependent cancers

Bernard Barlaam, Sabina Cosulich, Benedicte Delouvrie, Martina Fitzek, Herve Germain, Stephen Green, Craig S. Harris, Kevin Hudson, Christine Lambert-van der Brempt, Maryannick Lamorlette, Le Griffon Antoine, Remy Morgentin, Gilles Ouvry, Ken Page, Georges Pasquet, Linette Ruston, Twana Saleh, Michel Vautier, Lara Ward

Cancer Res (2015) 75 (15_Supplement): 2830.

DOI: https://doi.org/10.1158/1538-7445.AM2015-2830

Published: 01 August 2015

View article

Journal Articles

Abstract 2665: High dose intermittent scheduling of AZD8835, a novel potent and selective inhibitor of PI3Kα and PI3Kδ, identifies potential treatment strategies for PIK3CA-dependent cancers

Kevin Hudson, Urs Hancox, Cath Trigwell, Phillippa Dudley, Lyndsey Hanson, Robert McEwen, Alys Jones, Marie Cumberbatch, Urszula Polanska, Rebecca Ellston, Oona Delpuech, Pablo Morentin Gutierrez, Lara Ward, Francisco Cruzalegui, Stephen Green

Cancer Res (2015) 75 (15_Supplement): 2665.

DOI: https://doi.org/10.1158/1538-7445.AM2015-2665

Published: 01 August 2015

View article

Journal Articles

Abstract P6-12-01: A phase I study evaluating AZD2014 in combination with fulvestrant in patients with ER+ advanced metastatic breast cancer

Howard Burris III, Patricia LoRusso, W Larry Gluck, Suzanne Jones, Muaiad Kittaneh, Erika Hamilton, Stephen Green, Wendy Burke, Donald Strickland, Elisabeth Oelmann, Manish Patel

Cancer Res (2015) 75 (9_Supplement): P6-12-01.

DOI: https://doi.org/10.1158/1538-7445.SABCS14-P6-12-01

Published: 01 May 2015

View article

Journal Articles

Abstract 3264: AZD8186: a potent selective inhibitor of PI3Kβ targeting PTEN-deficient tumours dependent on dysregulated PI3Kβ signalling.

Urs Hancox, Sabina Cosulich, Hannah Dry, Lynsey Hanson, Clare Crafter, Bernard Barlaam, Martina Fitzek, Lara Ward, Marie Cumberbatch, Steve Powell, Rebecca Ellston, Mandy Lawson, Steve Wedge, Liz Harrington, Stephen Green, Simon T. Barry

Cancer Res (2013) 73 (8_Supplement): 3264.

DOI: https://doi.org/10.1158/1538-7445.AM2013-3264

Published: 15 April 2013

View article

Journal Articles

Abstract 917: AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer

Sylvie M. Guichard, Zoe Howard, Dan Heathcote, Mark Roth, Gareth Hughes, Jon Curwen, James Yates, Armelle Logie, Sarah Holt, Christine M. Chresta, Barry R. Davies, Karine Malagu, Marc Hummersone, Sarah L. Pass, Stephen Green, Martin Pass

Cancer Res (2012) 72 (8_Supplement): 917.

DOI: https://doi.org/10.1158/1538-7445.AM2012-917

Published: 15 April 2012

View article

Journal Articles

The Aurora B kinase inhibitor AZD1152 demonstrates potent antitumor efficacy in preclinical models using a range of dosing routes and schedules

Robert Wilkinson, Rajesh Odedra, Simon Heaton, Stephen Wedge, Nicholas Keen, John Foster, Mike Waker, Julia Young, Kevin Foote, Madeleine Brady, Nigel Barrass, Dereck Amakye, Kirsten Mundt, Stephen Green

Cancer Res (2007) 67 (9_Supplement): 4358.

Published: 01 May 2007

View article

Journal Articles

AZD1152: A highly potent and specific aurora kinase inhibitor.

Robert W. Wilkinson, Nicholas Keen, Rajesh Odedra, Simon P. Heaton, Stephen R. Wedge, Kevin M. Foote, Andrew A. Mortlock, Frederic H. Jung, Nicola M. Heron, Madeleine C. Brady, Mike Walker, Liz Khatri, Nigel C. Barrass, John J. Foster, Stephen Green

Cancer Res (2006) 66 (8_Supplement): 1333–1334.

Published: 15 April 2006

View article

Journal Articles

Novel pyrazole- and thiazole-substituted quinazolines as potent aurora kinase inhibitors.

Andrew A. Mortlock, Kevin M. Foote, Nicola M. Heron, Frederic H. Jung, Nick Keen, Robert W. Wilkinson, Stephen R. Wedge, Madeleine C. Brady, Stephen Green, Liz Khatri, David McKillop

Cancer Res (2006) 66 (8_Supplement): 1343–1344.

Published: 15 April 2006

View article

Journal Articles

Development and characterization in vivo of an inhibitor with Aurora kinase A and B specificity

Robert W. Wilkinson, Nick Keen, Stephen R. Wedge, Rajesh Odedra, Simon Heaton, Elaine Brown, Stephen Brightwell, Frederick Jung, Nicola Heron, Andrew Mortlock, Jack Allen, Sarah Kearney, John R. Foster, Stephen Green

Cancer Res (2004) 64 (7_Supplement): 193–194.

Published: 01 April 2004

View article

Journal Articles

Which is the right Aurora? Targeting the kinase activity of Aurora B confers an advantage

Nick Keen, Claire Ditchfield, Stephen Taylor, Elaine Brown, Stephen Brightwell, Andrew Mortlock, Stephen Green

Cancer Res (2004) 64 (7_Supplement): 603.

Published: 01 April 2004

View article

Journal Articles

Chimeric Receptors Used to Probe the DNA-binding Domain of the Estrogen and Glucocorticoid Receptors

Stephen Green, Pierre Chambon

Cancer Res (1989) 49 (8_Supplement): 2282s–2285s.

Published: 15 April 1989

View article

NARROW

Abstract CT233: A phase I study evaluating continuous and intermittent AZD2014 in combination with fulvestrant in patients with ER+ advanced metastatic breast cancer

Abstract 4696: Combining AZD8186, an inhibitor of PI3Kbeta, with inhibitors of PI3Kalpha and mTORC1/2 gives comprehensive pathway suppression and enhanced antitumor activity in PTEN null tumors

Abstract 4719: Targeting interdependent signaling pathways to increase the durability and magnitude of response: promising combination therapy with dual mTORC1/2 inhibitors and CDK4/6 inhibitors

Abstract 2830: Discovery of AZD8835, a potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of PIK3CA-dependent cancers

Abstract 2665: High dose intermittent scheduling of AZD8835, a novel potent and selective inhibitor of PI3Kα and PI3Kδ, identifies potential treatment strategies for PIK3CA-dependent cancers

Abstract P6-12-01: A phase I study evaluating AZD2014 in combination with fulvestrant in patients with ER+ advanced metastatic breast cancer

Abstract 3264: AZD8186: a potent selective inhibitor of PI3Kβ targeting PTEN-deficient tumours dependent on dysregulated PI3Kβ signalling.

Abstract 917: AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer

The Aurora B kinase inhibitor AZD1152 demonstrates potent antitumor efficacy in preclinical models using a range of dosing routes and schedules

AZD1152: A highly potent and specific aurora kinase inhibitor.

Novel pyrazole- and thiazole-substituted quinazolines as potent aurora kinase inhibitors.

Development and characterization in vivo of an inhibitor with Aurora kinase A and B specificity

Which is the right Aurora? Targeting the kinase activity of Aurora B confers an advantage

Chimeric Receptors Used to Probe the DNA-binding Domain of the Estrogen and Glucocorticoid Receptors

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only